Salmen Teodor, Potcovaru Claudia-Gabriela, Bica Ioana-Cristina, Giglio Rosaria Vincenza, Patti Angelo Maria, Stoica Roxana-Adriana, Ciaccio Marcello, El-Tanani Mohamed, Janež Andrej, Rizzo Manfredi, Gherghiceanu Florentina, Stoian Anca Pantea
Doctoral School, "Carol Davila" University of Medicine and Pharmacy, 050474 Bucharest, Romania.
Department of Biomedicine, Neuroscience and Advanced Diagnostics, University of Palermo, 90133 Palermo, Italy.
Pharmaceuticals (Basel). 2024 Oct 3;17(10):1322. doi: 10.3390/ph17101322.
This systematic review is registered with CRD42024507397 protocol number and aims to compare the known data about retatrutide on long-term cardiovascular (CV) protection with tirzepatide, an incretin with recent proven CV benefits. The inclusion criteria were (i) original full-text articles that are randomized control or clinical trials; (ii) published within the last ten years; (iii) published in English; and (iv) conducted on adult human populations. The exclusion criteria were articles deruled on cell cultures or mammals. Studies were selected if they (1) included patients with type 2 diabetes mellitus (DM) and CV risk; (2) patients that received either tirzepatide or retatrutide; and (3) provided sufficient information such as the corresponding 95% confidence intervals or at least a sufficient -value. Studies were excluded if they were a letter to the editor, expert opinions, case reports, meeting abstracts, or reviews; redundant publications; or needed more precise or complete data. The seven included studies were assessed for bias with the Newcastle Ottawa scale, heterogenous, and emphasized the potential CV beneficial effect of type 2 DM (T2DM) therapies (glycemia, glycated A1c hemoglobin, body weight, lipid profile, blood pressure and renal parameter). Further, longer follow-up studies are necessary to verify the long-term CV protection, standardize the specific aspects of CV risk, and compare with subjects without T2DM for a more integrative interpretation of the CV effects independent of the improvement of metabolic activity.
本系统评价已在CRD42024507397方案编号下注册，旨在比较有关retatrutide长期心血管（CV）保护的已知数据与替尔泊肽（一种近期已证实具有CV益处的肠促胰岛素）。纳入标准为：（i）随机对照或临床试验的原始全文文章；（ii）在过去十年内发表；（iii）以英文发表；（iv）针对成年人群开展。排除标准为在细胞培养物或哺乳动物上进行的文章。若研究符合以下条件则被纳入：（1）纳入2型糖尿病（DM）且有CV风险的患者；（2）接受替尔泊肽或retatrutide的患者；（3）提供足够信息，如相应的95%置信区间或至少一个足够的P值。若研究为给编辑的信、专家意见、病例报告、会议摘要或综述；重复发表的文章；或需要更精确或完整的数据，则被排除。使用纽卡斯尔渥太华量表对纳入的七项研究进行偏倚评估，研究具有异质性，并强调了2型糖尿病（T2DM）治疗（血糖、糖化血红蛋白A1c、体重、血脂谱、血压和肾脏参数）潜在的CV有益作用。此外，需要进行更长时间的随访研究，以验证长期CV保护作用，规范CV风险的具体方面，并与无T2DM的受试者进行比较，以便更全面地解释独立于代谢活动改善之外的CV效应。
